STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City, President: Tomoyuki Asano) hereby announces that its drug for Boron Neutron Capture Therapy (BNCT) Steboronine® intravenous drip bag 9000mg/300mL (Generic name: Borofalan [10B]; hereinafter referred to as Steboronine®) was approved today by the Ministry of Health, Labour and Welfare of Japan for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.
STELLA PHARMA Receives Marketing and Manufacturing Approval in Japan for “Steboronine® Intravenous Drip Bag 9000mg/300mL
